Abstract
Objective: The variability of thyroid function tests (TFTs) during antithyroid drug (ATD) therapy and its association with adverse health outcomes have not been previously studied. The aim of this study was to evaluate the association of TFT variability and cardiovascular morbidity during ATD therapy. Design: Retrospective cohort study. Patients and Measurements: Hyperthyroid patients (n = 394) treated with ATD therapy at Tampere University Hospital between March 2016 and December 2018 were followed up for a median time of 1.5 years (interquartile range 0.8–2.0). The coefficients of variation (CVs) of the follow-up thyroid-stimulating hormone (TSH), free thyroxine (fT4) and free triiodothyronine (fT3) measurements were determined. The associations of TFT variability and baseline clinical factors with cardiovascular disease (CVD) -associated hospital visits were assessed with logistic regression analyses. Results: In the multivariable analyses, age (odds ratio [OR]: 1.06, 95% confidence interval [CI]: 1.03–1.09), male gender (OR: 2.33, 95% CI: 1.03–5.28) and fT4-CV (OR: 1.02, 95% CI: 1.01–1.04) were independent risk factors for cardiovascular morbidity, whereas baseline positive thyrotropin receptor antibodies (TRAbs) were associated with lower cardiovascular morbidity (OR: 0.29, 95% CI: 0.14–0.61). When the patients with baseline TRAb positivity were studied separately, fT4-CV was associated with cardiovascular morbidity (OR: 1.03, 95% CI: 1.00–1.05). Conclusions: During ATD therapy, fT4 variability is associated with an increased cardiovascular morbidity. Although positive TRAbs are associated with a lower cardiovascular morbidity compared with hyperthyroidism with negative autoantibodies, the variability of fT4 is associated with cardiovascular morbidity also in patients with positive TRAbs.
| Original language | English |
|---|---|
| Pages (from-to) | 428-436 |
| Journal | Clinical Endocrinology |
| Volume | 99 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2023 |
| Publication type | A1 Journal article-refereed |
Funding
This work was supported by a research grant from the Finnish Cultural Foundation, the Research funding provided by Tampere University Hospital and by the Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital and the Hospital District of South Ostrobothnia. The authors thank Esko Väyrynen, M.A., for revising the language of the manuscript.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- antithyroid agents
- cardiovascular diseases
- Graves disease
- hyperthyroidism
- thyroid function tests
- thyroid hormones
- thyrotropin receptors
Publication forum classification
- Publication forum level 1
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Endocrinology
Fingerprint
Dive into the research topics of 'Thyroid function test variability and cardiovascular morbidity in hyperthyroidism'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver